AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 AUG 13 - (NewsRx.com & NewsRx.net) -- DOR BioPharma, Inc., announced it has executed an exclusive worldwide license agreement with the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) to license issued U.S. patent and pending patent applications pertaining to all injectable uses of novel recombinant ricin A chain mutants as vaccines to protect against poisoning by ricin.
In January, the company announced an exclusive option agreement, which covers the development of nasal, pulmonary, and oral ricin vaccines.
Ralph Ellison, MD, CEO of DOR stated, "We are pleased that UT Southwestern chose DOR as a partner to develop its ricin vaccines. The expansion of our relationship will allow DOR to provide an additional vaccine candidate to governmental agencies under the proposed "Bioshield Act." We are developing injectable and nasal ricin vaccines through parallel development ...
Source: HighBeam Research, License agreement executed for rights to ricin vaccine technology.